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Introduction
In the UK, research continues to confirm that
people with certain chronic illnesses, such as
chronic lung disease and cardiac failure, represent
the ‘disadvantaged dying’ compared to those with
terminal cancer.1,2 But what is the situation for
people dying with advanced dementia and what is
the experience of their carers? Practical guidance
for clinicians is scarce. In Standard 7 of the
National Service Framework for Older People,3
which covers mental health, there is mention
neither of how care should be provided nor of
how patient choice should be ensured for people
with dementia at the end of life. In the UK, 5%
of the population aged 65 and over and 20% of
those aged 80 and over have dementia4; similar
prevalence figures are found in the USA.5 Current
predictions suggest that the number of people
with dementia will increase by 40% by 2026
and will double by 2050.3 The increased demand
for end-of-life care for people with dementia will
be associated with major social and economic
costs,6,7 but what is the current standard of
such care? How can the quality be improved?
And how should future services be configured
to cope with this increasing need? In this paper,
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we review current knowledge around end-of-life
care in dementia, discuss the clinical challenges
and ethical dilemmas presented to carers, consider
the difficulties in delivering such care and suggest
practical approaches to improve the quality of such
care.
End-of-life care for people with dementia –
current evidence
In the UK, over 40% of people with dementia die
in the community8,9: 9% at home, 25% in nursing
homes, and 56% in hospital.9 However, dementia
as a cause of death is underestimated, with one-
third of death certificates of people with dementia
failing to state this as a cause of death.10 Hospice
use by people with dementia is minimal8,11: less
than 2% of people in hospice care in the UK have
a primary diagnosis of dementia.8 In the USA this
figure is marginally higher at 7%,11 but the vast
majority of peoplewith dementiawill die in nursing
homes.12, 19
Most of the recent research examining the
quality of end-of-life care for people with dementia
originates from the USA.14, 16 In a retrospective
cohort study, comparing the care received in the
last year of life in nursing homes by people
who died with dementia (n = 1609) with those
who died from terminal cancer (n = 883), the
former received sub-optimal care in several areas.
The study demonstrated: an increased use of
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non-palliative interventions in people with demen-
tia (for example, 25% were tube-fed compared to
5% of people with cancer); inadequate treatment
of some symptoms; and a lack of advance-
care planning (for example, the records of 55%
of people with dementia recorded a ‘do not
resuscitate’ statement compared to 86% of people
with cancer).15 A parallel study, exploring the
end-of-life care received by people with advanced
dementia in nursing homes compared to those
who continued to live at home with support from
home-care services, also found less than optimal
care in both settings.14 The evidence on end-of-
life care in hospital settings in the USA is equally
concerning: in one study over 60% of people with
dementia admitted to a geriatric ward died with
high levels of suffering.16 A UK-based study, which
explored carers’ perspectives as a proxy measure
to represent the end-of-life experiences of people
with advanced dementia, revealed a high incidence
of untreated symptoms in people with dementia,
which persisted for longer than in patients with
cancer.8 In addition, people with dementia and
their families required more input from health
and social services than people with terminal
cancer.8 Although the provision of end-of-life care
in nursing homes in the UK has been studied in
some depth,17–19 specific research focused on the
end-of-life experiences of people with dementia in
such settings is lacking. So why do people with
advanced dementia and their families continue
to receive poor quality care at the final stage of
life? In the next section we discuss the difficulties
professional carers face in providing high quality
end-of-life care in dementia.
Difficulties in the provision of high quality
end-of-life care in dementia
These include: communication issues; a failure to
recognize dementia as a terminal illness; specific
management issues including challenging clinical
and ethical dilemmas; addressing carer needs;
and organizational factors relating to the present
delivery of health and community care in the UK.
Communication issues
Patients and relatives may not be aware of the
exact diagnosis of dementia, making discussion
and negotiation around end-of-ife care issues
difficult from an early stage.20 There is extensive
variation in the rate of disclosure of a diagnosis
of dementia, with carers informed more frequently
of the diagnosis than people with the illness.20
Euphemistic terms were more commonly used
in disclosing the diagnosis to people with
dementia than to their carers.21 Despite their
considerable training in communication skills,
between 28% and 42% of general practitioners
reported difficulty in disclosing a diagnosis of
dementia.21,22
As dementia progresses, a person’s cognitive and
communication abilities decline and it becomes
harder for both lay and professional carers to
ascertain accurately the wishes and needs of
the person with dementia.23 For those with
dementia in nursing homes, information and
observations from staff are often invaluable, but
a high staff turnover may lead to unreliable
reports and misinterpretation of the significance
of symptoms,24 with the creation of a ‘malignant
social environment’.25 In addition, when a person
with dementia leaves their home to live in a nursing
home in the UK, they may have to change their
general practitioner,24 severing this potentially
therapeutic relationship.26
Failure to recognize dementia as a terminal illness
Identifying dementia as a progressive illness would
allow those with dementia and their carers to
consider palliative-care approaches more readily
and at an earlier stage.27,28 Although, theoretically,
experts consider the advanced stages of dementia
to meet palliative-care criteria,29 practically, both
professional and lay carers appear to have difficulty
with this concept.15 On nursing-home admission,
only 1% of people with advanced dementia were
perceived by staff as having a life expectancy of
less than six months, yet 71% died within that
period.15 The National Centre for Health Statistics
did not include Alzheimer’s disease as a cause
of death until 1994.30 Much of this difficulty is
related both to the protracted length of time from
confirmation of a diagnosis of dementia to death,
currently quoted as between four to nine years,31–32
and to the problems clinicians have in identifying
the point at which care becomes palliative, which
arguably could be from the point of diagnosis.33
Specific prognostic markers for advanced
dementia, focused on a life expectancy of six
months, have been developed in the USA in order
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Table 1. Medical problems in advanced dementia23
Neurocognitive
• Progressive worsening of memory and other cognitive deficits
• Increasing confusion and disorientation with specific behavioural changes (apathy, aggression and agitation)
• Progressive worsening of speech leading to an inability to communicate
Functional
• Loss of mobility, becoming eventually bed-bound
• Loss of capacity for self-care, eventually becoming totally dependent
Nutritional
• Progressive loss of appetite, loss of capacity to swallow and inability to feed independently
• Increasing risk of aspiration
Complications
• Bladder and bowel incontinence
• Fever and infections (pneumonia, urinary tract)
• Pressure sores
to inform hospice admission criteria.34 The
guidance is based on scales which have attempted
to classify the progression of dementia into stages,
for example, the Global Deterioration Scale,35 and
the Functional Assessment Staging (FAST) Scale.36
For a person with dementia to qualify for hospice
admission, they must be at or beyond FAST Stage
7, i.e. they have lost the capacity for mobility and
self-care, have no meaningful communication and
are incontinent of bladder and bowel function.36
Although such scales are not entirely accurate, they
have been shown to predict a six-month mortality
of approximately 60%.37
Clinical challenges in end-of-life care for people
with dementia
Routine clinical care
The advanced stages of dementia are associated
with a consistent range of medical problems
(see Table 1).23 For example, mental confusion
occurs in 83%, urinary incontinence in 72%,
pain in 64%,8 swallowing problems in 72% and
malnutrition in 50%.38
Antibiotic treatment of intercurrent infections
is less effective in dementia39 because several risk
factors (e.g. an inability to report symptoms,
decreased immune responses to infections and
loss of ability to ambulate) make infections an
unavoidable consequence of advanced dementia.
Non-randomized studies also indicate that antibio-
tic treatment is not necessary to maintain comfort
during an intercurrent infection.40 Nutritional pro-
blems in dementia include weight loss, food refusal
and difficulties chewing and swallowing.41 Food re-
fusal may be managed by diet modification and by
administration of antidepressants42 or dronabinol
(which is not available in the UK).43 Chewing dif-
ficulties and choking may be minimized by modifi-
cations of diet texture. Aspiration resulting from
choking may be prevented by ACE inhibitors44
and amantadine.45 Tube-feeding does not prevent
aspiration or provide other benefits.46 It poses a
burden for the personwith dementia47 and deprives
them of the enjoyment of taste and interaction with
caregivers during feeding. Even if tube-feeding is
initiated, it can be converted to natural feeding.48
Decreased life expectancy49 makes inadvisable
the use of preventive interventions that have only
long-term consequences, such as restricted diets,
and intensive treatment of chronic conditions such
as hypertension. Aphasia leads to an inability to
report symptoms of diseases,50 but also symptoms
caused by over-treatment or distress induced by
medical procedures. Some medical procedures
routinely performed for cognitively intact indi-
viduals may not be appropriate for individuals
with advanced dementia. Cardio-pulmonary
resuscitation (CPR) is not indicated because of
the low probability of survival and great burden
imposed by the procedure.51 Even in a hospital,
CPR is three times less likely to be successful in
patients with dementia than in patients who are
cognitively intact, and the success rate is almost as
low as in metastatic cancer.52 Transfer to a hospital
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for treatment of intercurrent infections may not be
indicated because treatment in a nursing home has
a better outcome.53,54
Management of distress and pain
As dementia progresses, the loss of cognitive and
communication abilities makes the assessment of
distress in a person with dementia a complex
issue. ‘Distress’ can have a variety of causes: pain;
delirium; depression; agitation or psychosis; social
isolation; immobility or drug-related side-effects.55
The consequences of pain are far reaching,
affecting sleep, mobility, immunity56 and mental
state,57,58 yet it is currently notoriously under-
diagnosed and inadequately treated,56,59–61 for
example, patients with severe dementia received
less opioid analgesia post-hip fracture than their
cognitively intact peers.61
The experience and expression of pain in
dementia is attracting interest, with attempts to
link it to the neuropathological characteristics of
illness subtypes. Central to this, is the degree to
which medial and lateral pain systems are affected.
In Alzheimer’s disease damage to the medial
pain system predominates. This plays a pivotal
role in the motivational-affective processing of
pain, and translates clinically into reduced pain
intensity and increased tolerance.61,62 The relative
preservation of pain thresholds has also been
observed in Alzheimer’s disease.61 These factors
have implications for the clinical utility of some
observational pain scales.
Recognizing pain can be difficult in patients
with communication difficulties.63 Self-report is
not feasible, and identification rests with carers.8
Recent years have seen the emergence of pain
tools, which have sought to tackle problems of
under-recognition and under-documentation in
this group. The PAINAD, (Pain Assessment in
Advanced Dementia)64 derived from the DS-DAT
(Discomfort in Dementia of Alzheimer’s Type), has
five items – breathing, negative vocalization, facial
expressions, body language and consolability.
When compared with two visual analogue scales,
PAINAD was effective in assessing pain but
the study was limited in its sample size.64 The
NOPPAIN (Non-Communicative Patient’s Pain
Assessment Instrument) was designed for use by
nursing assistants at times of intervention.65 The
tool was deemed valid but the study was again
limited by sample size. A novel component of the
ADD (Assessment of Discomfort in Dementia) is
its stepwise inclusion of pharmacological and non-
pharmacological interventions.56 The Abbey Pain
Scale borrows its design from previous tools and,
therefore, features indicators and prompts with
established validity: it appears to be valid, well-
received by users and easily completed.66
In the treatment of pain in dementia, non-drug
treatments (e.g. massage, TENS, aromatherapy.
etc.) should also be included in the therapeutic
options, but robust evidence for their use is
lacking.67 The World Health Organization’s
(WHO) analgesic ladder has been adopted in some
settings.68 It recommends the timely administration
of analgesia, starting with non-opioids and work-
ing progressively to strong opioids, until the patient
is pain-free. ‘Adjuvant’ treatments are also em-
ployed, such as tricyclic antidepressants and anti-
convulsants.69 Although tools to assess pain in
dementia56,64,66 and guidance on pain mana-
gement68 exist, the unacceptably high number of
people suffering16,70 clearly indicates the need for
further research and interdisciplinary collabo-
ration.60
Behavioural and psychological symptoms
in dementia (BPSD)
Ninety per cent of people develop behavioural and
psychological symptoms in dementia (BPSD).71
The management of BPSD is challenging, with
two-thirds of general practitioners and 50% of
hospice staff37 lacking confidence in this area.
More than 80% of people with dementia residing
in care facilities have behavioural or psychiatric
symptoms,72 with symptoms of agitation (in-
cluding aggression and restlessness) occurring in
over half. The frequency of these symptoms, the
distress that they can cause,73 the potential risk
to other residents and the burden upon carers74
have made the treatment of these symptoms
a high clinical priority. Theoretically, non-
pharmacological interventions are recommended
before pharmacological methods.75
A wide range of the former exist, such as
electronic tagging and tracking devices, be-
havioural approaches (e.g. reality-orientation),
distraction therapies (e.g. exercise, music therapy),
alternative therapies (e.g. homeopathy), environ-
mental modifications and subjective barriers, but
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evidence on their effectiveness is scanty.76,77 Also,
the high levels of staff turnover,78 the absence
of an appropriate skill-mix and staff shortages
in most care-facility settings has rendered the
systematic application of non-pharmacological
management techniques unfeasible. This has led to
an increased imperative to utilize drug treatments,
but unfortunately with an inadequate evidence-
base to inform clinical practice.
Neuroleptic drugs are the most widely-used
pharmacological therapy used to treat BPSD
and are prescribed in up to 60% of people
with dementia in nursing homes,72,79 often for
prolonged periods, with a median duration of
prescription in excess of one year.72 Whilst there
is clear evidence of benefit across more than
20 randomized placebo controlled trials (20%
advantage over placebo) over periods of six to
12 weeks,80 the placebo response rate is very
high (>40%) and the overall benefit in terms
of quality of life has not been evaluated. Of
even greater concern considering the patterns
of prescribing in clinical practice, the evidence of
longer-term efficacy is far less clear, with only one
placebo-controlled trial of greater than 12 weeks,
which showed no benefit with neuroleptic
treatment,81 and a number of randomized
controlled-withdrawal trials suggesting no signi-
ficant exacerbation of neuropsychiatric symptoms
when long-term prescriptions of neuroleptics
are discontinued.82–84 In addition to established
side-effects such as parkinsonism and drowsiness,
there are serious risks potentially associated
with neuroleptic drugs. These include a threefold
increased risk of stroke/cerebrovascular events,85
an almost twofold increased mortality,86 oedema,
falls and reduced quality of life,87 and accelerated
cognitive decline.81,88 People with dementia
residing in nursing homes are a very frail and
vulnerable group of people, with an average life
expectancy of only two years.89 It is therefore a
source of major concern that this widespread use of
neuroleptic treatments may increase the likelihood
of serious detrimental outcomes, including death,
and impair the quality of life of these individuals.
End-of-life care experiences for families of people
with dementia
The experience of families who care for people
with dementia has been likened by some to ‘coping
with a living death’.90 A number of models have
been outlined to describe the caregiving trajectory
in dementia,91–98 with Lindgren applying the
term ‘caregiver career’.95 This encompasses three
distinct but overlapping stages: an Encounter Stage
(the diagnosis and loss of previous life-patterns), an
Enduring Stage (managing extensive care-routines
and social isolation) and, finally, an Exit Stage
(the relinquishment of caregiving through the
death of the spouse or their admission into care).95
Sweeting and Gilhooly, either independently99
or jointly,100,101 pioneered the application of
the constructs of ‘anticipatory grief’ and ‘social
death’ to the process of caregiving and dementia.
Whatever term is used, carers generally consider
the person’s death as ‘a relief’102,105 in contrast to
the general literature on bereavement.106,108
Such families face particular stresses in compar-
ison to other caregiving groups109,110and experi-
ence greater detrimental effects in terms of physical
and mental health and social isolation.7 A variety
of interventions have been developed to help, such
as support groups,111,112 training programs,113
family-based psychosocial interventions114–116 and
specialist community care,117,118 each with differ-
ent outcomes and levels of efficacy at various stages
of the caregiving trajectory.119,120 In general, carers
of people with advanced dementia require more
emotional support and respite care prior to the per-
son’s death than afterwards,121 and the more social
support they receive pre-bereavement, the better
adjusted they are post-bereavement.122–124
There are a number of areas concerning family
carers of people with dementia which require
more exploration, e.g. end-of-life decision-making,
especially for family carers with relatives in
residential care,125,126 the adequate preparation of
family carers for their loved one’s death122–124 and
measuring quality of life at the end of life.127,128
Shock and devastation amongst carers following
the death of the person with dementia is associated
with a lack of foresight.129 Appropriate informa-
tion and intervention strategies should be provided
throughout the caregiving trajectory, so that the
terminal phase is demystified and feared a little less.
The introduction of Admiral nurses, with specialist
knowledge and experience in dementia care and
carer support,130 may provide an opportunity to
address this, although initial results show little
difference in both carer and patient outcomes,
whether carers receive support from this service
or existing community mental health teams.131
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Ethical issues at the end of life
The unique aspect of ethical issues in dementia
relates to the increasing and unavoidable need
for others to take decisions for the person with
dementia. The question is, what justifies these
decisions? In many cases, they are justified by
reference to the evidence for the effectiveness
of the particular action. But in most cases the
decisions are difficult precisely because they involve
clinical and ethical aspects, for example, those
involving artificial nutrition and hydration (ANH)
in dementia.132 From a meta-analysis showing that
artificial feeding did not achieve its objectives,
Gillick argued against the use of percutaneous
endoscopic gastrostomy (PEG) feeding.133 Such
arguments are justified by the ethical principles of
beneficence and non-maleficence.134 Subsequently
Gillick considered the use of ANH at different
stages in the person’s dementia.135 These decisions
are difficult because they rely on there being a clear
distinction between the person whose condition
will lead to death at some stage and the person
who is already moribund. In a condition such as
dementia, deciding how close to death a person is
may not always be straightforward. In addition,
such decisions do not solely depend on medical
matters as they affect the individual, since they
also involve families. Research suggests that the
simple application of the principles of medical
ethics with respect to ANH decisions is not always
helpful.136 In an ethnographic study inHolland, the
wishes of the family were found to be important
in making these decisions, but so too were the
medical condition of the patient and judgements
about quality of life.137 These factors were more
important than living wills and policy agreements.
Such studies show a mixture of clinical and
ethical issues coming together in connection with
difficult decisions. The range of decisions in the
later stages of dementia that raise ethical issues is
too broad to be surveyed in detail,138,139 but the
brief discussion of ANH already points towards
the importance of autonomy and how death comes
about. It has been recognized for some time that
autonomy is a complicated notion.140 It seems to
rely on an atomistic view of people as rational and
discrete individuals, rather than as interrelated and
interconnected, dependent selves, embedded in a
history and context.141 A fuller view of autonomy
supports and is supported by a broader view of the
person with dementia.142 This conception of the
person helps to justify (and ought to encourage) the
greater willingness to involve families in decisions
concerning death and dying.143 It is, after all, part
of the holism of the palliative-care approach that
family carers ought to be involved in decisions,
especially in dementia.144
It is not always clear how to ascertain the
person’s autonomous wishes. Legislation in
various countries supports the use of advance
directives, but advance directives are not always
easy to interpret in concrete situations.146 Where
the person’s views are not definitively known,
carers are required to act in his or her best
interests and the advance directive might then
help as a guide to what might be best. But the
determination of what is best for someone should
be broad-based, recognizing the continuities in
terms of dependence, and the character and body
that go to make up the self.146 It is certainly
relevant to note that the person with dementia can
be encouraged, even in the severer stages of the
disease, to participate in decisions.147 The person’s
awareness or lack of awareness (and, therefore,
his or her ability to participate in decision-making)
may be a function of the social environment.148
The end of life in severe dementia raises further
difficult ethical considerations. For instance, the
issue of withholding or withdrawing treatment is
again one that has to be decided on both clinical
and ethical grounds. It is possible that predictors
will be found to suggest when antibiotic therapy
should be used and when it should be withheld in
people with severe dementia.149 However, there
is still an ethical decision to be made about how
hard to treat the person. The distinction between
ordinary and extraordinary means, when this is
understood in terms of the burdens imposed by
the particular treatment against the likelihood of
benefits accruing to the person concerned, has
traditionally been found useful.159 It would still
require an evaluative judgement to decide when
treatments were burdensome in this way.
Values theory and practice provide a way to
approach the conflicts that arise when judgements
are based on conflicting values.151 The key is to
try to place the values of the person concerned
centre stage, but to give space to the values of
others. People’s decisions cannot be presumed.
In a study of 52 older people in nursing homes
in Australia, who were given a hypothetical case
of someone with recurrent aspiration pneumonias
and severe dementia, most of the participants
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(61.5%, p<0.1) preferred the idea of hospital ad-
mission and 73.1% (p < 0.001) said they would
choose antibiotic treatment.152 Negotiating these
ethical dilemmas requires practical wisdom on the
part of the clinician. Practical wisdom is the sort of
virtue or disposition commended by virtue ethicists
as a way of dealing with moral dilemmas that
arise at the end of life.153 But the virtues are
acquired through experience and practice. Virtue
ethics stress what we become by doing or not doing
certain things. It requires that weight is put on the
value of caring itself, as an activity that demon-
strates human flourishing. From this point of view,
palliative care (with its acceptance of death) seems
more appropriate for people with severe dementia
than the thought that their lives should be ended
by either active or passive euthanasia.154,155 In any
event, the ubiquity of clinico-ethical decisions at
the end of life in dementia calls out for specialized
knowledge and skill.
Improving end-of-life care for people with
dementia – adopting a palliative-care approach
The World Health Organization recently stated
that ‘every person with a progressive illness has a
right to palliative care’.156 The continuing inequit-
ies in terminal care between people with cancer
and other chronic illnesses has led to an impetus
in the UK to extend the provision of palliative
care to people with non-malignant disease.157 Both
professional carers and lay carers of people with
dementia favor a palliative-care approach in ad-
vanced dementia,158,159 however, there is currently
little evidence for the efficacy of a palliative-care
model in dementia compared to traditional care,
although the research base is poor.160 Palliative
care is defined as ‘the active total care of patients
and families by a multi-professional team when the
patient’s disease is no longer responsive to curative
treatment’.161 The concept of palliative care incor-
porates both a general ‘palliative-care approach’,
to promote both physical and psychological well-
being from all professional carers involved, and the
provision of specialist palliative-care services from
hospice-based palliative-care teams.162
In the USA, a palliative-care approach has been
adopted in some areas for people with dementia
and specialist units akin to hospices have been
established.163,164 When the provision of palliative
care in a dementia special care unit (DSCU) was
compared to traditional long-term care units,
the DSCU was both more effective clinically and
economically than traditional care, with more
evidence of advanced-care planning, less invasive
care and lower average three-month costs in the
DSCU.164 However, examples of such specialist
care are rare, with only a small number of people
with dementia accessing hospice care.8,11
Nevertheless, would a specialist hospice appro-
ach for end-of-life care for people with dementia be
appropriate in the UK? Nearly half the people with
dementia in the UK will die in nursing homes,8 and
transferring people in the late stages of dementia
from what has become their ‘home’, may be more
detrimental to their quality of life than beneficial.24
In addition, the provision of end-of-life care for
people with dementia in the USA is affected by
different factors, for example, financial reimburse-
ments to physicians for ‘hospitalized’ patients
exceed those for nursing home visits.27 Such factors
heavily influence how future care is planned.
Priorities for education and service organization
Despite the limited evidence-base,160 it would
seem that palliative care represents an important
and sensible alternative to conventional care in the
advanced stages of dementia.17,158,159 However,
professional carers appear to experience difficulties
in adopting a general palliative-care approach in
dementia.15 So how can we overcome existing
barriers27 and ensure that such an approach is
promoted in advanced dementia and that people
with dementia receive high quality end-of-life
care?
Having acknowledged the communication
difficulties that exist for carers in talking to people
with dementia, we need to understand why it is so
difficult for professionals to use the word ‘demen-
tia’ explicitly, and how this process can be achieved
in a sensitive and person-centred way.20 Training
packages already exist for helping professionals
improve their individual skills in consultations
where communication difficulties exist.165,166 For
if the diagnosis were empathetically discussed at an
early stage, it would enable people with dementia
to express their wishes when they were mentally
capable. This might encourage the use of advance
statements to help carers deliver more person-
centred care in the advanced stages of the disease.24
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Currently only 11% of people dying with dementia
have made a living will.15
In contrast to cancer care,167,168 there is
currently little practical guidance on the provision
of end-of-life care in dementia.3 Care pathways
have been developed to transfer the specialist
palliative care received in hospices at the end of
life into other care settings.167,168 The Liverpool
Care Pathway (LCP)168 and the Gold Standards
Framework (GSF)168 have been shown to support
measurable improvements in the quality of end-of-
life care and are recommended by NICE.169 Such
models however are limited to care in the last few
days of life and their development is grounded in
a cancer-care model. The principle of developing a
similar care pathway for advanced dementia care
might produce similar demonstrable improvements
in quality, improve education and facilitate more
integrated care.168,170 In the USA, the Palliative
Excellence in Alzheimer Care Efforts (PEACE) pro-
gram was developed to integrate a palliative-care
approach into dementia care.171 It incorporates
advance planning, patient-centred care, family sup-
port and a palliative-care focus from the diagnosis
of dementia. Initial results have shown adequate
pain control and appropriate attention paid to
patient wishes, and choice in location of death.171
Professionals working in the community need
access to specialist expertise to provide end-of-
life care in dementia.172 Unfortunately, the Audit
Commission found that specialist support for
managing people with advanced dementia was not
available at all in 40% of all areas of the UK,172
and even dementia-care specialists lack confidence
in providing palliative care.173 A multidisciplinary
approach is therefore required, with a wide range
of specialities, for example, old age psychiatry,
palliative care, speech therapy, primary and
community care, specialist nursing and carer
support (for example, Admiral nurses).130 Such
expertise is readily available but it is not currently
organized in a co-ordinated and integrated way for
dementia care.24 The creation of a community-
based team specializing in the management of
advanced dementia, and including such expertise,
would facilitate more integrated care and allow
specialist advice to be provided, regardless of where
a person with dementia was living.24 Such teams
could be directly accessed by any professional carer
including nursing-home staff.19 Another possibility
for the provision of more seamless care could be
through the national extension of the Admiral
nursing service.130 Although further evidence is
required of its effectiveness,131 such a service could
provide opportunities similar to the introduction of
McMillan nurses for cancer care i.e. a key source
of specialist help for both primary and secondary
care professionals.
In addition to improving general palliative care,
the evidence for the effectiveness of a specialist hos-
pice service for people with dementia is limited,164
especially in the UK. However, existing NHS
continuing-care beds could provide the opportun-
ity to develop such a specialist unit, which could act
as a base for the advanced dementia-care team and
provide a source of inpatient beds, should specialist
care be required.33 In conclusion, it would appear
that much needs to be done to improve the
quality of dying for people with dementia, both in
the provision of specialist palliative-care services
and in the facilitation of a general palliative-care
approach. From a review of current evidence, it
would seem that people dying with dementia do
truly represent the ‘disadvantaged dying’.
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